

APPLICANT(S): STEINER, Mitchell S. et al.  
SERIAL NO.: 10/747,691  
FILED: December 30, 2003  
Page 2

RECEIVED  
CENTRAL FAX CENTER

NOV 19 2007

#### AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1. (Currently amended) A method of treating a subject with hot flashes, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof, wherein said anti-estrogen is Toremifene.
2. -4. Cancelled.
5. (Original) The method according to claim 1, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.
6. (Original) The method according to claim 5 wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.
7. (Currently amended) The method according to claim 1, wherein ~~said antiestrogen~~ Toremifene is administered at a dosage of about 20 mg per day.
8. (Currently amended) The method according to claim 1, wherein ~~said antiestrogen~~ Toremifene is administered at a dosage of about 40 mg per day.

APPLICANT(S): STEINER, Mitchell S. et al.  
SERIAL NO.: 10/747,691  
FILED: December 30, 2003  
Page 3

9. (Currently amended) The method according to claim 1, wherein said ~~antiestrogen~~ Toremifene is administered at a dosage of about 60 mg per day.
10. (Currently amended) The method according to claim 1, wherein said ~~antiestrogen~~ Toremifene is administered at a dosage of 80 mg per day.
11. (Withdrawn) A method of suppressing, inhibiting or reducing the risk of hot flashes, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.
12. (Withdrawn) The method according to claim 11, wherein the anti-estrogen is a selective estrogen receptor modulator (SERM).
13. (Withdrawn) The method according to claim 11, wherein the anti-estrogen is a triphenylethylene.
14. (Withdrawn) The method according to claim 11, wherein the anti-estrogen is Toremifene.
15. (Withdrawn) The method according to claim 11, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.
16. (Withdrawn) The method according to claim 15, wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

APPLICANT(S): STEINER, Mitchell S. et al.  
SERIAL NO.: 10/747,691  
FILED: December 30, 2003  
Page 4

17. (Withdrawn) The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
18. (Withdrawn) The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 40 mg per day.
19. (Withdrawn) The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
20. (Withdrawn) The method according to claim 11, wherein said antiestrogen is administered at a dosage of 80 mg per day.
21. (Withdrawn) A method of treating a subject with gynecomastia, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.
22. (Withdrawn) The method according to claim 21, wherein said anti-estrogen is a selective estrogen receptor modulator (SERM).
23. (Withdrawn) The method according to claim 21, wherein said anti-estrogen is a triphenylethylene.
24. (Withdrawn) The method according to claim 21, wherein said anti-estrogen is Toremifene.
25. (Withdrawn) The method according to claim 21, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical

APPLICANT(S): STEINER, Mitchell S. et al.  
SERIAL NO.: 10/747,691  
FILED: December 30, 2003  
Page 5

composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.

26. (Withdrawn) The method according to claim 25 wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.
27. (Withdrawn) The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
28. (Withdrawn) The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 40 mg per day.
29. (Withdrawn) The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
30. (Withdrawn) The method according to claim 21, wherein said antiestrogen is administered at a dosage of 80 mg per day.
31. (Withdrawn) A method of suppressing, inhibiting or reducing the risk of gynecomastia, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.
32. (Withdrawn) The method according to claim 31, wherein the anti-estrogen is a selective estrogen receptor modulator (SERM).
33. (Withdrawn) The method according to claim 31, wherein the anti-estrogen is a triphenylethylene.
34. (Withdrawn) The method according to claim 31, wherein the anti-estrogen is

APPLICANT(S): STEINER, Mitchell S. et al.  
SERIAL NO.: 10/747,691  
FILED: December 30, 2003  
Page 6

Toremifene.

35. (Withdrawn) The method according to claim 31, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.
36. (Withdrawn) The method according to claim 35, wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.
37. (Withdrawn) The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
38. (Withdrawn) The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 40 mg per day.
39. (Withdrawn) The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
40. (Withdrawn) The method according to claim 31, wherein said antiestrogen is administered at a dosage of 80 mg per day.